Browse the evidence

Endoscopic sleeve gastroplasty (ESG) is safe and effective in patients with a BMI of 27-30, with a mean total weight loss of 11.0% at 6 months and 15.5% at 12 months.

Practitioners can consider ESG as a viable option for overweight patients seeking weight loss.

Liraglutide (3.0 mg daily) and semaglutide (2.4 mg weekly) are FDA-approved GLP-1 receptor agonists for weight management.

Practitioners can consider liraglutide and semaglutide as viable options for patients needing weight management.

Incretin-based therapies, including GLP-1 receptor agonists like semaglutide and tirzepatide, can improve quality of life, exercise tolerance, and markers of HF severity while promoting weight loss in patients with obesity and HFpEF.

Practitioners may consider incretin-based therapies as effective treatment options for improving health outcomes in patients with obesity-related HFpEF.

Semaglutide can be used safely and efficiently in non-diabetic people with excess weight.

Semaglutide may be considered as a treatment option for weight management in non-diabetic patients.

Endurance exercise positively influences muscle protein turnover rates in people with obesity.

Incorporating HIIT may help improve muscle health in individuals with obesity.

A produce prescription program significantly improved HbA1c among low-income patients on Medicaid with poor glycemic control at baseline.

Implementing produce prescription programs may help improve glycemic control in low-income diabetic patients.

HbA1c at 6 months was significantly reduced in the intervention group compared to control.

The intervention may be effective in lowering HbA1c levels in similar patient populations.

GLP-1 receptor agonists have demonstrated efficacy and safety in treating type 2 diabetes and obesity.

GLP-1 receptor agonists can be considered effective options for managing type 2 diabetes and obesity.

New pharmacologic advances in glucagon-like peptide-1 agonists, such as semaglutide, have shown promising effectiveness for weight management.

Plastic surgeons should consider the role of GLP-1 agonists in managing obesity in surgical patients.

Semaglutide and tirzepatide are effective medication options for obesity management.

Practitioners can consider semaglutide and tirzepatide as viable options for treating obesity.

Patients in the semaglutide group experienced greater weight loss compared to the control group (−8.2% vs. −4.6%; P <0.001).

Semaglutide may be effective for weight management in patients post-ablation.

Tirzepatide demonstrates unprecedented efficacy for glycaemic control, reductions in body weight, and improvements in blood pressure and lipid profile compared with placebo and GLP-1 receptor agonists.

Tirzepatide may be a highly effective treatment option for managing glycaemic control and weight in patients with T2D and obesity.

Bariatric surgery effectively improves the management of obesity and inhibits the progression of multiple metabolic diseases.

Bariatric surgery should be considered as a viable option for managing obesity and related metabolic conditions.

With the inclusion of dietary supplements, percentages below the EAR for all nutrients (except protein) were lower than those for food alone.

Incorporating dietary supplements may help mitigate nutrient deficiencies in calorie-restricted diets.

Reductions in fat mass (FM) by 10% are associated with a lower risk of kidney outcomes (adjusted HR 0.80, 95% CI 0.69-0.94) in participants with overweight/obesity and type 2 diabetes mellitus (T2DM) in the intensive lifestyle intervention group.

Practitioners should consider promoting fat loss as a strategy to reduce kidney disease risk in patients with T2DM.

Reductions in waist circumference (WC) by 10% are associated with a lower risk of kidney outcomes (adjusted HR 0.72, 95% CI 0.59-0.88) in participants with overweight/obesity and T2DM in the intensive lifestyle intervention group.

Practitioners should encourage reductions in waist circumference to help lower kidney disease risk in T2DM patients.

Single-set resistance training performed to failure elicits greater hypertrophy gains compared to submaximal effort, although differences are modest.

Practitioners may consider incorporating training to failure for enhanced muscle growth.

Both training to failure and submaximal effort result in similar increases in strength and local muscular endurance.

Both training methods can be effective for improving strength and endurance.

Short-term resistance training combined with leucine-enriched protein supplementation increases integrated myofibrillar protein synthesis (MyoPS) rates in young adults.

Incorporating leucine-enriched protein bars may enhance muscle protein synthesis during resistance training.

Short-term resistance training increases integrated myofibrillar protein synthesis (MyoPS) compared to rest.

Resistance training is effective for increasing muscle protein synthesis.

Leucine-enriched protein supplementation enhances anabolic protein signaling compared to rest.

Supplementing with leucine can improve anabolic signaling during resistance training.

Multi-ingredient supplementation (MIS) resulted in a greater increase in type II fiber cross-sectional area (fCSA) following 10 weeks of resistance exercise training (RET) compared to collagen supplementation (COL) (effect size = 0.89).

Practitioners may consider recommending multi-ingredient protein supplements to enhance muscle fiber growth during resistance training.

Sodium bicarbonate ingestion increased the number of repetitions performed in the third set of the bench press exercise (g: 0.30; p = 0.046).

Ingesting sodium bicarbonate may enhance performance in resistance training, particularly in later sets.

Sodium bicarbonate ingestion increased the total number of repetitions performed throughout all 3 sets in the bench press exercise (g: 0.23; p = 0.04).

Sodium bicarbonate may improve overall performance in resistance training sessions.